NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Normunity

Normunity

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://normunity.com/

Last Round

Series B

Jan 13, 2025

Est. Valuation

$500M

Total Funding Raised

$140M

Company Overview

Normunity is a biotechnology company that develops precision immuno-oncology therapies designed to restore the immune system's natural ability to identify and eliminate cancer cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immuno-oncologyt-cell engagersolid tumorsprecision medicinedrug discoverybiotechtumor microenvironmentclinical trialscancer immunotherapybiotechnologytherapeutic candidatesnovel drug mechanismsbiopharmapreclinical developmentpipeline development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Normunity Comps

Public and private peers based on sector, stage, and business model.

Normunity comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Normunity Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 13, 2025
Series AOct 25, 2022

Key People

Founding team and executive leadership

Rachel W. Humphrey

President And Founding CEO

Founding Team

Normunity Investors

Notable investors and investment history

Normunity investors
InvestorRounds
Enavate SciencesSeries B
Connecticut InnovationsSeries B
Taiho VenturesSeries B, Series A
Osage University PartnersSeries B, Series A
HongShanSeries B
Canaan PartnersSeries B, Series A
Pfizer VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 4, 2026

    Will participate in the TD Cowen 46th Annual Health Care Conference.

  • Jan 13, 2025

    $75M round with a $500M post-money valuation.

Normunity Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Normunity Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Normunity's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range25
Year Founded2020
Last FundingJan 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.